Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of therapy for low-level viremia in HBeAg-positive chronic hepatitis B after nucleos(t)ide analogue treatment
ChiCTR2500109821Phase 4Recruiting
- Sponsor
- Department of Infectious Diseases, Changhai Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide and tenofovir in Chronic Hepatitis B (CHB) (5 arms), sponsored by Department of Infectious Diseases, Changhai Hospital. Primary endpoints: Rate of complete virological response at 24 weeks and Rate of complete virological response at 48 weeks. Started Sep 2025; status: recruiting.
02
Drugs
entecavirtenofovir disoproxil fumaratetenofovir alafenamidetenofovir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2500109821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109821.